← Back to Search

Nudges for MRI Screening in Women with Dense Breasts

N/A
Waitlist Available
Led By Anne Marie McCarthy, PhD
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Provider needs to have ordered the initial screening mammogram
Women aged 40-74
Must not have
Prior history of breast cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

This trial aims to see if sending reminders can increase the use of MRI scans among women with extremely dense breasts. These women are at higher risk for breast cancer, and MRIs can detect tumors that regular mammograms might miss. The study hopes these reminders will lead to better cancer detection.

Who is the study for?
This trial is for women aged 40-74 with extremely dense breasts who had a non-actionable mammogram within the last 6 months at specified Penn Medicine locations. They must have a valid mobile number, and their provider should have ordered the initial mammogram. Women with prior breast cancer or recent MRI/ultrasound are excluded.
What is being tested?
The study tests if 'nudges' to either patients, providers, or both can increase breast MRI screenings among women with very dense breasts. It also examines if there's a difference in response between Black and White women.
What are the potential side effects?
Since this trial involves nudging interventions rather than medical treatments, traditional side effects like those seen with medications are not applicable.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My doctor has ordered my first mammogram.
Select...
I am a woman aged between 40 and 74.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had breast cancer before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ordering and/or scheduling of supplemental breast MRI
Secondary study objectives
Cancer detection rate
Completion of breast MRI
False-positive rate
+2 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Provider nudge onlyExperimental Treatment1 Intervention
Nudge sent to provider through EHR.
Group II: Patient nudge onlyExperimental Treatment1 Intervention
Nudge sent to the patient through text messaging.
Group III: Patient and provider nudgeExperimental Treatment2 Interventions
Nudge sent to both provider through EHR, and to patient through text messaging.
Group IV: Usual care (no nudge)Active Control1 Intervention
Usual standard of care, no nudging.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for breast cancer include hormone therapy, HER2-targeted therapy, and chemotherapy. Hormone therapy works by blocking hormones like estrogen that can promote the growth of hormone receptor-positive breast cancer cells. HER2-targeted therapy, such as trastuzumab, targets the HER2 protein on cancer cells, inhibiting their growth and survival. Chemotherapy uses cytotoxic drugs to kill rapidly dividing cancer cells. These treatments are crucial as they target specific mechanisms that drive cancer growth, improving survival rates and quality of life for patients. Behavioral encouragement, like nudging, can enhance treatment adherence and utilization, further optimizing patient outcomes.
Progress in psychosocial and behavioral cancer research. The need for enabling strategies.

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor
409 Previous Clinical Trials
157,273 Total Patients Enrolled
45 Trials studying Breast Cancer
59,267 Patients Enrolled for Breast Cancer
University of PennsylvaniaLead Sponsor
2,060 Previous Clinical Trials
42,646,006 Total Patients Enrolled
27 Trials studying Breast Cancer
24,770 Patients Enrolled for Breast Cancer
Anne Marie McCarthy, PhDPrincipal InvestigatorUniversity of Pennsylvania

Media Library

Provider nudge only Clinical Trial Eligibility Overview. Trial Name: NCT05787249 — N/A
Breast Cancer Research Study Groups: Usual care (no nudge), Provider nudge only, Patient nudge only, Patient and provider nudge
Breast Cancer Clinical Trial 2023: Provider nudge only Highlights & Side Effects. Trial Name: NCT05787249 — N/A
Provider nudge only 2023 Treatment Timeline for Medical Study. Trial Name: NCT05787249 — N/A
~800 spots leftby Oct 2025